Loncar Cancer Immunotherapy ETF (CNCR)
CNCR is a passive ETF by Exchange Traded Concepts tracking the investment results of the Loncar Cancer Immunotherapy Index. CNCR launched on Oct 13, 2015 and has a 0.79% expense ratio.
ETF Info
US26922A8264
26922A826
Oct 13, 2015
Developed Markets (Broad)
1x
Loncar Cancer Immunotherapy Index
Multi-Cap
Blend
Expense Ratio
CNCR has an expense ratio of 0.79%, placing it in the medium range.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Loncar Cancer Immunotherapy ETF (CNCR) returned -27.54% year-to-date (YTD) and -41.32% over the past 12 months.
CNCR
-27.54%
-1.68%
-33.18%
-41.32%
-15.17%
-18.69%
N/A
^GSPC (Benchmark)
1.39%
12.89%
1.19%
12.45%
15.19%
14.95%
10.86%
Monthly Returns
The table below presents the monthly returns of CNCR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0.57% | -8.04% | -17.17% | 6.15% | -10.89% | -27.54% | |||||||
| 2024 | 5.12% | 21.96% | -3.76% | -11.19% | -1.76% | -6.86% | 13.29% | -1.44% | -0.86% | -2.47% | -1.58% | -14.22% | -8.61% |
| 2023 | 8.15% | -9.42% | -10.86% | 5.51% | 5.07% | -2.78% | 0.15% | -7.11% | -8.86% | -11.64% | 13.69% | 22.40% | -1.89% |
| 2022 | -18.55% | -4.92% | -2.33% | -14.02% | -10.07% | 9.14% | 5.33% | -3.08% | -5.51% | 2.38% | -0.60% | -7.91% | -42.31% |
| 2021 | 3.51% | -3.99% | -5.04% | 3.07% | -0.84% | 4.23% | -7.01% | 3.07% | 1.21% | -6.75% | -7.15% | -4.35% | -19.24% |
| 2020 | -10.04% | 2.67% | -9.77% | 16.33% | 16.58% | 2.25% | -6.91% | 6.71% | 2.04% | -3.91% | 22.61% | -1.07% | 36.53% |
| 2019 | 9.48% | 5.18% | -3.28% | -2.57% | -5.45% | 9.01% | 2.21% | -9.72% | -3.71% | 5.29% | 18.79% | -0.09% | 24.19% |
| 2018 | 18.31% | 1.84% | 1.41% | -9.81% | 7.25% | -14.09% | 0.47% | 5.88% | -3.31% | -20.26% | 8.37% | -12.03% | -20.62% |
| 2017 | 3.68% | 7.01% | 3.10% | -3.83% | -8.56% | 7.77% | 1.22% | 10.34% | 5.21% | -5.03% | -3.11% | -3.10% | 13.58% |
| 2016 | -27.42% | -3.24% | 8.19% | 4.64% | 4.40% | -4.13% | 7.71% | -1.62% | 7.18% | -18.44% | 7.84% | -6.42% | -25.62% |
| 2015 | 10.20% | 11.36% | -6.90% | 14.25% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CNCR is 0, meaning it’s performing worse than 100% of other ETFs on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Loncar Cancer Immunotherapy ETF provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $1.85 | $0.29 | $0.00 | $0.00 | $0.35 | $0.00 | $0.11 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 7.79% | 0.91% | 0.00% | 0.00% | 1.47% | 0.00% | 0.37% |
Monthly Dividends
The table displays the monthly dividend distributions for Loncar Cancer Immunotherapy ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.85 | $1.85 |
| 2020 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.29 | $0.29 |
| 2019 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2018 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2017 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.35 | $0.35 |
| 2016 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2015 | $0.11 | $0.11 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Loncar Cancer Immunotherapy ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Loncar Cancer Immunotherapy ETF was 75.85%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Loncar Cancer Immunotherapy ETF drawdown is 73.11%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -75.85% | Feb 9, 2021 | 1045 | Apr 8, 2025 | — | — | — |
| -49.98% | Mar 13, 2018 | 506 | Mar 16, 2020 | 180 | Nov 30, 2020 | 686 |
| -39.92% | Nov 30, 2015 | 51 | Feb 11, 2016 | 518 | Mar 5, 2018 | 569 |
| -9.59% | Oct 16, 2015 | 4 | Oct 21, 2015 | 8 | Nov 2, 2015 | 12 |
| -6.97% | Jan 20, 2021 | 7 | Jan 28, 2021 | 7 | Feb 8, 2021 | 14 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...